Clinical Utility of Longitudinal Measurement of Motor Threshold in Wilson’s Disease

Abstract

Abstract:This study describes the longitudinal changes of resting motor threshold (RMT) and central motor conduction time (CMCT) in 18 patients with Wilson’s disease (WD). The RMT, CMCT, and Global Assessment Scale for Wilson Disease (GAS-WD) were measured at baseline and at follow-up after 12.94 ± 7.23 months. There was a significant decrease in the RMT (72.11 ± 18.62 vs. 63.7 ± 15.52%; p-value = 0.002) and GAS-WD scores (14.38 ± 5.35 vs. 9.77 ± 6.47 ms; p-value = 0.04). CMCT did not improve despite chelation therapy. Hence, RMT may serve as a marker of chelation efficacy in WD.

A comprehensive review of transcranial magnetic stimulation in secondary dementia

“…The TMS group included 4 studies on NPH (Zaaroor et al, 1997;Chistyakov et al, 2012;Nardone et al, 2019a;Agrawal et al, 2021), 11 on MS (Cucurachi et al, 2008;Mori et al, 2011Mori et al, , 2013Canham et al, 2015;Hofstadt-van Oy et al, 2015;Nantes et al, 2016;Chalah et al, 2018Chalah et al, , 2019Chaves et al, 2019Chaves et al, , 2021a, 6 on CD and other immune-mediated disorders (Pennisi et al, 2014;Bella et al, 2015;Pennisi et al, 2017;Tokimura et al, 2020;Fisicaro et al, 2021b;Lanza et al, 2021), 5 on endocrine disorders (Ozata et al, 1996;Rizzo et al, 2008;Terranova et al, 2016;Fried et al, 2017Fried et al, , 2019, 13 on liver and renal diseases (Meyer et al, 1991;Nolano et al, 1997;Córdoba et al, 2003;Battaglia et al, 2005;Cerri et al, 2010;McDonald et al, 2010;Dubbioso et al, 2016;Golaszewski et al, 2016;Nardone et al, 2016b;Groiss et al, 2019;Hassan et al, 2019;Stezin et al, 2019;Dubbioso et al, 2020), 9 on nutritional and alcohol-related disorders (Wu and Chu, 1996;Oishi and Mochizuki, 1999;…”

“…The TMS group included 4 studies on NPH ( Zaaroor et al, 1997 ; Chistyakov et al, 2012 ; Nardone et al, 2019a ; Agrawal et al, 2021 ), 11 on MS ( Cucurachi et al, 2008 ; Mori et al, 2011 , 2013 ; Canham et al, 2015 ; Hofstadt-van Oy et al, 2015 ; Nantes et al, 2016 ; Chalah et al, 2018 , 2019 ; Chaves et al, 2019 , 2021a , b ), 6 on CD and other immune-mediated disorders ( Pennisi et al, 2014 ; Bella et al, 2015 ; Pennisi et al, 2017 ; Tokimura et al, 2020 ; Fisicaro et al, 2021b ; Lanza et al, 2021 ), 5 on endocrine disorders ( Ozata et al, 1996 ; Rizzo et al, 2008 ; Terranova et al, 2016 ; Fried et al, 2017 , 2019 ), 13 on liver and renal diseases ( Meyer et al, 1991 ; Nolano et al, 1997 ; Córdoba et al, 2003 ; Battaglia et al, 2005 ; Cerri et al, 2010 ; McDonald et al, 2010 ; Dubbioso et al, 2016 ; Golaszewski et al, 2016 ; Nardone et al, 2016b ; Groiss et al, 2019 ; Hassan et al, 2019 ; Stezin et al, 2019 ; Dubbioso et al, 2020 ), 9 on nutritional and alcohol-related disorders ( Wu and Chu, 1996 ; Oishi and Mochizuki, 1999 ; Ravaglia et al, 2002 ; Misra et al, 2003 ; Atanassova et al, 2004 ; Di Lazzaro et al, 2004 ; Nardone et al, 2006 , 2010b , 2016a ), 7 on infectious or inflammatory diseases ( Misra and Kalita, 1998 ; Kalita and Misra, 2002 ; Lo and Ratnagopal, 2007 ; Volz et al, 2016 ; Nardone et al, 2019b ; Ortelli et al, 2021 ; Versace et al, 2021 ), 5 on sleep disorders (…”

“…Another recent study has described the longitudinal changes of rMT and CMCT in 18 WD patients. A progressive decrease of rMT was observed, whereas CMCT did not improve despite chelation therapy, thus suggesting that rMT may serve as a marker of chelation efficacy ( Stezin et al, 2019 ).…”